Kansas City, MO,
10
October
2018
|
21:06 PM
Europe/Amsterdam

Goldman Receives RO1 Grant from NIH

Jennifer Goldman, MD, Director of the Antimicrobial Stewardship Program and the Drug Safety Service in the Division of Infectious Diseases and Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children's Mercy Kansas City, has been awarded a five-year, $1,364,567 R01 grant from the National Institute of General Medical Sciences.

Dr. Goldman’s “Trimethoprim: an overlooked contributor of trimethoprim-sulfamethoxazole idiosyncratic adverse drug reactions” study will define mechanisms associated with trimethoprim induced adverse reactions, the drug component which has been overlooked and understudied as a likely contributor to idiosyncratic adverse drug reactions. This information is critical for the future development of tools that can predict those at greatest risk and thereby enhance safe prescribing of this critical antibiotic.

Boilerplate

Children’s Mercy Kansas City is an independent, non-profit, 386-bed pediatric health system, providing over half a million patient encounters each year for children from across the country. Children’s Mercy is ranked by U.S. News & World Report in nine specialties. We have received Magnet® recognition five times for excellence in nursing services. In affiliation with the University of Missouri-Kansas City, our faculty of more than 800 pediatric specialists and researchers is actively involved in clinical care, pediatric research and educating the next generation of pediatricians and pediatric subspecialists. The Children’s Mercy Research Institute (CMRI) integrates research and clinical care with nationally recognized expertise in genomic medicine, precision therapeutics, population health and health care innovation. In 2021 the CMRI moved into a nine-story, 375,000-square-foot space emphasizing a translational approach to research in which clinicians and researchers work together to accelerate the pace of discovery that enhances care.